ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
Phase 2 Study of Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
Protocol ID
SJiMB21
Disease (Sub Disease)
Medulloblastoma
Diagnosis Stage
Newly diagnosed
Sponsor
Australian and New Zealand Children's Haematology Oncology Group
St. Jude Children's Research Hospital
Links
External Registry ≫
Trial Status
Preparing to Open
Study Type
Treatment
Phase
Phase 2
Age Eligibility
up to 59 Months
International registry ID's
NCT05535166
Back to Registry
Study Title Phase 2 Study of Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
Protocol ID SJiMB21
Disease (Sub Disease) Medulloblastoma
Diagnosis Stage Newly diagnosed
Sponsor Australian and New Zealand Children's Haematology Oncology Group/ St. Jude Children's Research Hospital
Links https://clinicaltrials.gov/ct2/show/NCT05535166
Trial Status Preparing to Open
Study Type Treatment
Phase Phase 2
Age Eligibility up to 59 Months
International registry ID's NCT05535166

Join our newsletter

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Email info@anzchog.org   |  

Level 6, TRF Building, Hudson Institute, 27-31 Wright St, Clayton VIC 3168

ANZCHOG acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait Islander cultures, and to Elders both past and present. We acknowledge Māori as tangata whenua of Aotearoa New Zealand and as Treaty partners with the Crown as agreed in Te Tiriti o Waitangi. 

We are committed to creating a safe and welcoming environment that embraces all backgrounds, cultures, sexualities, genders and abilities.